Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous HPV16/HPV18/Survivin-specific CD8+ T cells NEXI-003

A preparation of autologous CD3+ CD4- CD8+ T cells targeting multiple human papilloma virus (HPV) tumor-associated antigens, including HPV types 16 and 18 antigens and survivin, with potential immunomodulating and antineoplastic activities. Following leukapheresis and ex vivo priming and expansion, the autologous HPV16/HPV18/survivin-specific CD8+ T cells NEXI-003 are re-introduced into the patient, where they target and kill tumor cells expressing these HPV tumor-associated antigens.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous HPV tumor-relevant antigen-specific CD8+ T cells NEXI-003 CD3+ CD4- CD8+ T cells NEXI-003
Code name:	NEXI 003 NEXI-003 NEXI003

autologous HPV16/HPV18/Survivin-specific CD8+ T cells NEXI-003

Search NCI's Drug Dictionary